For instance, miR-345 inhibits the proliferation, migration, and epithelial-mesenchymal transition (EMT) of GC cells by targeting forkhead box Q1 (FoxQ1) [44]; miR-127 curbs GC cell migration and invasion by targeting Wnt7a [45]; miR-1265 suppresses GC progression and oncogenic autophagy by inhibiting calcium-binding protein 39 (CAB39) expression and regulating the AMPK-mTOR signaling pathway [46]; miR-17, miR-25, and miR-133b in circulating serum could be introduced as potential diagnostic candidates applicable for use with early-stage GC patients [47]. Here, MTOR is linked to gastric cancer.